MERSANA THERAPEUTICS Reports Q2 FY2023 Revenue Increase of 148.8% Year-Over-Year

August 28, 2023

☀️Earnings Overview

MERSANA THERAPEUTICS ($NASDAQ:MRSN) reported their second quarter FY2023 earnings results on June 30 2023, with total revenue of USD 10.7 million, a 148.8% increase from the same period in the previous year. Net income stood at USD -54.3 million, an improvement from the -52.2 million reported a year ago.


Analyzing MERSANA THERAPEUTICS fundamentals with GoodWhale reveals that the company is strong in terms of assets and growth but weak in dividends and profitability. The company is classified as a “cheetah”, meaning it achieved high revenue or earnings growth but is considered less stable due to lower profitability. This could make it interesting to investors looking for higher-risk opportunities with potential for high returns. However, it is important to take into account the health score of MERSANA THERAPEUTICS, which is 3/10 with regard to its cash flows and debt. This implies that the company is less likely to sustain future operations in times of crisis. Therefore, investors should exercise caution when considering investing in MERSANA THERAPEUTICS as there is a risk of financial losses. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Mersana Therapeutics. More…

    Total Revenues Net Income Net Margin
    38.72 -215.21 -555.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Mersana Therapeutics. More…

    Operations Investing Financing
    -87.47 -65.96 146.82
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Mersana Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    311 221.2 0.75
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Mersana Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    183.8% -545.9%
    FCF Margin ROE ROA
    -232.4% -171.4% -42.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s lead product candidate, XMT-1536, is in clinical development for the treatment of solid tumors. Mersana has two other ADC product candidates in development, XMT-1522 and XMT-1592. Mersana’s main competitors are Sensei Biotherapeutics Inc, IMV Inc, and Immunome Inc. These companies are also focused on developing cancer therapies, including ADCs.

    – Sensei Biotherapeutics Inc ($NASDAQ:SNSE)

    Sensei Biotherapeutics Inc is a clinical-stage immuno-oncology company. The company is focused on developing and commercializing its proprietary platform of off-the-shelf, anti-sense oligonucleotide therapeutics to treat a range of solid tumors and hematologic malignancies.

    – IMV Inc ($TSX:IMV)

    IMV Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of cancer immunotherapies and other immune modulating agents. Its product candidates include DPX-Survivac, T cell Receptor, and Antibody Programs. The company was founded by Frederic Ors on December 15, 1999 and is headquartered in Halifax, Canada.

    – Immunome Inc ($NASDAQ:IMNM)

    Immunome Inc is a clinical stage biopharmaceutical company that focuses on the development of monoclonal antibody therapeutics for the treatment of cancer. The company has a market cap of 56.88M as of 2022 and a return on equity of -65.38%. The company’s focus on the development of monoclonal antibody therapeutics for the treatment of cancer makes it a unique player in the biopharmaceutical industry. The company’s clinical stage status also makes it a high-risk investment, but one that could offer high rewards if the company’s products are successful in the marketplace.


    Mersana Therapeutics reported their second quarter of FY2023 earnings, showing total revenue of USD 10.7 million, a 148.8% year-over-year increase. Net income was -USD 54.3 million, a slight improvement compared to FY2022’s -USD 52.2 million. For potential investors, this indicates that the company is continuing to grow with revenue and profitability increasing overall.

    However, investors should be aware that net income remains in the red and will need to be monitored carefully. Overall, Mersana Therapeutics looks like a company with potential that requires further research for investors interested in pursuing it.

    Recent Posts

    Leave a Comment